Decapeptide-12

Key Benefits#

• Reduces hyperpigmentation and dark spots
• Evens skin tone and improves radiance
• Inhibits post-inflammatory hyperpigmentation
• Well-tolerated alternative to hydroquinone
• Effective for melasma and age spots
• Non-cytotoxic to melanocytes

Mechanism of Action#

Decapeptide-12 competitively inhibits tyrosinase, the rate-limiting enzyme in melanin biosynthesis, at the copper-binding active site. It also downregulates MITF (microphthalmia-associated transcription factor) expression and reduces tyrosinase-related protein-1 (TRP-1) and TRP-2 levels, providing multi-pathway inhibition of melanogenesis. Unlike hydroquinone, it does not cause melanocyte cytotoxicity.

Dosing Protocols#

Side Effects#

• Generally very well-tolerated
• Rare mild irritation or sensitivity in some skin types
• Results may take several weeks to become visible

Contraindications#

Allergy to peptide ingredientsNot studied in pregnancy; caution advised

Storage#

Store at room temperature away from direct sunlight. Peptide stability is maintained best in pH 5–7 formulations. Avoid temperature extremes.

1. 1.
   Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles

   Chen J, Bian J, Hantash BM, Albakr L, Hibbs DE, Xiang X et al. · International journal of pharmaceutics · 2021PubMed Verified

2. 2.
   Efficacy of Trifecting(®) Night Cream, a Novel Triple acting Skin Brightening Product: A Double-blind, Placebo-controlled Clinical Study

   Jiang L, Hino PD, Bhatia A, Stephens TJ, Jimenez F · The Journal of clinical and aesthetic dermatology · 2018PubMed Verified

3. 3.
   Combined topical delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color

   Bhatia A, Hsu JTs, Hantash BM · Journal of drugs in dermatology : JDD · 2014PubMed Verified

4. 4.
   Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma

   Ramírez SP, Carvajal AC, Salazar JC, Arroyave G, Flórez AM, Echeverry HF · Journal of drugs in dermatology : JDD · 2013Clinical TrialPubMed Verified

5. 5.
   Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system

   Hantash BM, Jimenez F · Journal of drugs in dermatology : JDD · 2012Case ReportPubMed Verified

6. 6.
   Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12

   Kassim AT, Hussain M, Goldberg DJ · Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2012Clinical TrialPubMed Verified

7. 7.
   A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma

   Hantash BM, Jimenez F · Journal of drugs in dermatology : JDD · 2009RCTPubMed Verified